Infergen

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
interferon alfacon-1	DDMAC reviewed a journal advertisement with a brief summary for Infergen (interferon alfacon-l) and found it to be false and misleading because it overstated the product's efficacy but omitted and minimized risk information. InterMune, Brisbane, CA, March 28 (DDMAC) by Warning Letter Bulletin In addition to three-times-a-week Infergen (interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, InterMune has a broad and deep late-stage product portfolio addressing IPF and HCV infections, particularly nonresponders, or those patients who do not respond to first-line therapy. Intermune issued of two composition of matter patents for Actimmune by BIOTECH Patent News NON-SPECIFIC ANTIVIRALS AND IMMUNE MODULATORS Phase 3 studies InterMune's Infergen (consensus interferon) is an alternate form of interferon approved as monotherapy for hepatitis C treatment in the 1990s, but seldom used. The hepatitis C drug development pipeline by Raymond, Daniel / Research Initiative/Treatment Action!	infectious bulbar paralysis infectious disease infectious eczematoid dermatitis infectious endocarditis infectious gastritis infectious granuloma infectious hepatitis infectious isolation infectious mononucleosis infectious mononucleosis syndrome infectious myringitis infectious nucleic acid infectious papilloma virus infectious parotitis infectious period infectious polyneuritis infectious warts virus infectious-exhaustive syndrome infective infective embolism infective endocarditis infective tubulointerstitial nephritis infectivity inference inferential statistics Infergen inferior inferior alveolar artery inferior alveolar nerve inferior anastomotic vein inferior aperture of minor pelvis inferior aperture of thorax inferior artery of knee inferior basal vein inferior capsular shift inferior carotid triangle inferior cerebellar peduncle inferior cerebral vein inferior cervical cardiac nerve inferior cervical ganglion inferior choroid vein inferior cluneal nerve inferior colliculi inferior conjunctival fornix inferior constrictor muscle of pharynx inferior dental plexus inferior epigastric vein inferior ganglion of glossopharyngeal nerve inferior ganglion of vagus inferior gastric node inferior gemellus muscle	Inference rules inference statistics inference statistics inference statistics inference statistics Inference technique Inference technique Inference technique Inference technique Inferences Inferences Inferences Inferences inferencing inferential inferential inferential inferential inferential flow meter inferential liquid-level meter Inferential Retrieval Index System Inferential statistics Inferential statistics Inferential statistics Inferential statistics Inferential statistics inferentially inferentially inferentially inferentially Infergen Inferi Dii Inferi Dii Inferiae inferior inferior inferior inferior Inferior alveolar Inferior alveolar Inferior alveolar inferior alveolar artery inferior alveolar artery inferior alveolar artery Inferior alveolar block Inferior alveolar block inferior alveolar nerve inferior alveolar nerve inferior alveolar nerve inferior alveolar nerve Inferior Alveolar Nerve Block Inferior Alveolar Nerve Block Anesthesia Inferior Alveolar Neurovascular Bundle Inferior alveolar vessels Inferior alveolar vessels Inferior alveolar vessels Inferior anal nerves inferior anastomotic vein Inferior and superior planets Inferior and superior planets Inferior aperture

Mentioned in

References in periodicals archive

Medical browser

Full browser

DDMAC reviewed a journal advertisement with a brief summary for Infergen (interferon alfacon-l) and found it to be false and misleading because it overstated the product's efficacy but omitted and minimized risk information.

InterMune, Brisbane, CA, March 28 (DDMAC) by Warning Letter Bulletin

In addition to three-times-a-week Infergen (interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, InterMune has a broad and deep late-stage product portfolio addressing IPF and HCV infections, particularly nonresponders, or those patients who do not respond to first-line therapy.

Intermune issued of two composition of matter patents for Actimmune by BIOTECH Patent News

NON-SPECIFIC ANTIVIRALS AND IMMUNE MODULATORS Phase 3 studies InterMune's Infergen (consensus interferon) is an alternate form of interferon approved as monotherapy for hepatitis C treatment in the 1990s, but seldom used.